CAS 128-13-2 Supplement 98% Ursodeoxycholic Acid Udca Powder Ep9 Grade

We are the most professional real "MANUFACTURER" and "SUPPLIER" of CHOLIC ACID series materials on MIC, welcome the enquiry from both Foreign and Domestic customers.

We can provide:

(1) Cholic Acid (Free Grade 50%)                                                             CAS #:81-25-94

(2) Cholic Acid (Food Grade 90%)                                                            CAS #:81-25-94

(3) Cholic Acid (Pharmaceutical Grade 95%;98%)                                CAS #:81-25-94

(4) Chenodeoxycholic Acid(intermediate of Ursodeoxycholic Acid)      CAS #:474-25-9

(5) 3alpha-Hydroxy-7-oxo-5beta-cholic acid(7K-LCA)                           CAS #:4651-67-6

(6) Ursodeoxycholic Acid(EP9/USP/IP GRADE WITH GMP)               CAS #:128-13-2 

(7)Tauroursodeoxycholic acid   EP9                                                           CAS #:14605-22-2
(8)Obeticholic Acid  (OBCA)  98%/99%                                                   CAS #:459789-99-2
(9)Obeticholic Acid Intermediate-1(OB N-1)                                            CAS #:915038-26-5
(10)Obeticholic Acid Intermediate-2(OB N-2)                                          CAS #:1516887-33-4
(11)Obeticholic Acid Intermediate-3(OB M-2)                                          CAS#:1352328-66-5
 

Description:

Product Name:Ursodeoxycholic acid

CAS:128-13-2
Molecular Formula: C₂₄H₄₀04
Molecular Mass:392.58
[Appearance]: white crystal powder, no foreign substance, no obvious odor
[Melting Point]:203~2062.0ºC
[Loss on Dry]: ≤1.0%
[Residue on Ignition]: ≤0.1%
[Heavy Metal ]: ≤10ppm
[Assay Determination]: 98.0%~101.0% (dries basis)
[Related Substance]:the single impurity≤0.1%, total impurities≤2.0%
[Package and Storage Condition]: 25kg/drum, store and seal away from light
 

What is URSODEOXYCHOLIC ACID?
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a secondary bile acid, produced in humans and most other species from metabolism by intestinal bacteria. It is synthesized in the liver in some species, and was first identified in bear bile, which is the derivation of its name Ursus.

Medical uses:
UDCA has been used as medical therapy in gallstone disease (cholelithiasis) and for biliary sludge. UDCA helps reduce the cholesterol saturation of bile and leads to gradual dissolution of cholesterol-rich gallstones.
UDCA may be given after bariatric surgery to prevent cholelithiasis, which commonly occurs due to the rapid weight loss producing biliary cholesterol oversaturation and also biliary dyskinesia secondary hormonal changes.

Primary biliary cholangitis
UDCA is used as therapy in primary biliary cholangitis (PBC; previously known as primary biliary cirrhosis) where it can produce an improvement in biomarkers. Meta-analyses have borne out conflicting results on the mortality benefit.However analyses that exclude trials of short duration (i.e. < 2 years) have demonstrated a survival benefit and are generally considered more clinically relevant. A Cochrane systematic review in 2012 found no significant benefit in reducing mortality, the rate of liver transplantation, pruritus or fatigue. Ursodiol and obeticholic acid are FDA-approved for the treatment of primary biliary cholangitis.
Primary sclerosing cholangitis[
UDCA use is associated with improved serum liver tests that do not always correlate with improved liver disease status. WHO Drug Information advises against its use in primary sclerosing cholangitis in unapproved doses beyond 13-15 mg/kg/day.
Intrahepatic cholestasis of pregnancy
UDCA has been used for intrahepatic cholestasis of pregnancy. UDCA lessens itching in the mother and may reduce the number of preterm births. Effects on fetal distress and other adverse outcomes are unlikely to be great.
Cholestasis
UDCA use is not licensed in children, as its safety and effectiveness have not been established. Evidence is accumulating that ursodeoxycholic acid is ineffective and unsafe in neonatal hepatitis and neonatal cholestasis.
Other conditions
UDCA has been suggested to be an adequate treatment of bile reflux gastritis.
In cystic fibrosis there is insufficient evidence to justify routine use of UDCA, especially as there is a lack of available data for long-term outcomes such as death or need for liver transplantation.
UDCA has also been used in non-alcoholic fatty liver disease, in liver bile duct-paucity syndromes such as biliary atresia, liver allograft rejection, and in Graft-versus-host disease involving the liver.
Ursodeoxycholic acid, the main component is 3a, 7β-dihydroxy-5β-cholestane-24-acid, is an organic compound, odorless and bitter. This product is soluble in ethanol, insoluble in chloroform; soluble in glacial acetic acid, dissolved in sodium hydroxide solution. Medically used to increase the secretion of bile acid, and to change the composition of bile, reduce cholesterol and cholesterol in bile, is conducive to gradual dissolution of cholesterol in gallstones.  

For the treatment of gallstones, cholestatic liver disease, fatty liver, various types of hepatitis, toxic liver disorders, cholecystitis, biliary and biliary dyspepsia, bile reflux gastritis, eye diseases.

QINGDAO HAOSAIL COA OF UDCA EP8


QINGDAO HAOSAIL COA OF URSODEOXYCHOLIC ACID USP



QINGDAO HAOSAIL  INVESTED CHOLIC ACID SERIES MANUFACTURER GMP CERTICIFICATION